Cargando…
Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
A recent study reported that patients with interstitial lung disease (ILD) are at increased risk of death from coronavirus disease 2019 (COVID-19). However, there are no studies on the outcome of COVID-19 patients with preexisting ILD treated with corticosteroids or antiviral drugs. We extracted 26...
Autores principales: | Yamaya, Takafumi, Hagiwara, Eri, Baba, Tomohisa, Iwasawa, Tae, Ogura, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995204/ https://www.ncbi.nlm.nih.gov/pubmed/35422381 http://dx.doi.org/10.1016/j.jiac.2022.04.006 |
Ejemplares similares
-
Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021) -
Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
por: Sakayori, Masashi, et al.
Publicado: (2023) -
Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy
por: Sasano, Hajime, et al.
Publicado: (2016) -
Prognostic Factors in Interstitial Lung Disease Associated with Primary Sjögren’s Syndrome: A Retrospective Analysis of 33 Pathologically–Proven Cases
por: Enomoto, Yasunori, et al.
Publicado: (2013) -
COVID-19 Pneumonia Resembling an Acute Exacerbation of Interstitial Pneumonia
por: Kitayama, Takaaki, et al.
Publicado: (2020)